Conor Killmurray

Articles

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12th 2021

In the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large b-cell lymphoma in the outpatient setting who are receiving the CAR T-cell therapies prior to failure on 2 prior lines of therapy.

Regorafenib/Pembrolizumab Combination Yields Encouraging Results in Advanced HCC

June 10th 2021

The combination of regorafenib plus pembrolizumab in the first-line setting for patients with advanced hepatocellular carcinoma showed encouraging anti-tumor activity with a disease control rate of 91%, and did not display any new safety signals.

Tucatinib Concentrations in CSF Demonstrated in HER2+ Metastatic Breast Cancer

June 4th 2021

Evidence of tucatinib and its predominant metabolite, ONT-993, were detectable in the cerebrospinal fluid of patients with leptomeningeal metastasis HER2+ positive breast cancer marking a first for tucatinib distribution into the CSF seen in this patient population.

Ruxolitinib Delivered at Maximum Dose Peri-Transplant Proves Safe in Myelofibrosis

February 10th 2021

February 10, 2021 - The JAK 1/2 inhibitor ruxolitinib, when given at a maximum dose of 10 mg peri-transplant, has been shown to be safe and feasible in patients with myelofibrosis.

GI AEs Associated With Oral Paclitaxel Plus Encequidar Subside with Antiemetics, Loperamide in Metastatic Breast Cancer

December 11th 2020

December 11, 2020 - Gastrointestinal adverse events that occurred in patients with metastatic breast cancer who were treated with oral paclitaxel and encequidar can be managed by the use of 5- HT3 inhibitors and early intervention with loperamide.

Regardless of Timing, Smoking Cessation Before Lung Cancer Diagnosis Shows Survival Benefit

May 13th 2020

People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.